Archives: Speakers

Vivek Mahadevan joined Siemens Energy in 2008 and has a background in product engineering, specialising in the mechanical design and structural integrity of steam turbine and gas turbine components (rotors and casings).

For the last few years, his role as an engineering technical lead has focussed on developing solutions globally to enable stability of the electrical grid, by converting existing gas and steam turbo-generator power plants.

He has worked on the overall integrated plant solution from initial development to final implementation, including the rotating mechanical shaft line, balance of plant, auxiliary systems, civil interfaces, electrical integration, and interface with the grid.

Harvard educated (BA Biology, JD, MPH), exceptionally well-rounded, and award winning life sciences venture capitalist with operating, entrepreneurial, legal (IP & FDA) and pharmaceutical management consulting experience and a science background. An entrepreneurial journey as a female founder and CEO “growing up” on the tech side (digital health) makes me a unique biotech investor with a founder friendly bent and a lean startup mindset.

20 years of biopharma and healthcare industry experience. Board Director or Observer of 8 biotechs with 3 exits in 2 years. Led/Shepard 3 large pharma deals (AZ, Pfizer, Takeda).

Skilled in life sciences and healthcare venture investing, board governance, BD, strategy, management, fundraising/startup operations, IP law, Food & Drug regulation, tech transfer, and cross-border international business with Asia.

Christina has over 20 years experience in Pharma holding various positions within Clinical Operations, Medical Affairs, Project Management, and the last 5 years in Global Clinical Supply Chain.

Throughout the course of her career, she has provided support across all phases of Sponsor Clinical Studies at Incyte, GSK, Bristol Myers Squibb, and Gilead Sciences, as well as management of Expanded Access Programs and Investigator initiated trials.

She currently holds the position of Director, Global Clinical Supply Chain at Incyte, with a focus in patient-centric forecasting, strategic planning, and distribution of drug supply for Incyte’s portfolio.

As Head of Compliance at the WSTA Kelly deals with compliance and food regulatory matters. She leads on low and no which includes acting as secretariat to the WSTA’s Low and No Working Group, a group formed to support WSTA members in producing, labelling and promoting LoNo alcohol products in the UK. Kelly also acts as secretariat for the Retail of Alcohol Standards Group, The British Wine and Made Wine Producers Committee and the Direct-To-Consumer Committee. Her background is as a Trading Standards Officer, and she enjoyed running her own Food Labelling Consultancy business prior to joining the WSTA in 2017.

Nicole Stansbury, Senior Vice President, Global Clinical Operations, is responsible for oversight of clinical operations which includes clinical strategy and delivery, study start up, central monitoring, and site management and risk-based monitoring at Premier Research. She leverages an innovative, data-driven approach and more than 25 years of industry experience to help sponsors address the rapidly evolving demands of the clinical development industry. In her role, Stansbury is focused on finding ways to simplify process and improve technology adoption to decrease the time, cost, complexity, and risk of delivering clinical research.

Prior to joining Premier Research, Stansbury held various CRO leadership positions where she was instrumental in the strategic implementation of risk-based monitoring, central monitoring and continuous improvement of clinical operations processes. Stansbury has been co-lead for the Association of Clinical Research Organizations Risk-Based Monitoring (ACRO RBM) Working Group working with TransCelerate and the FDA since 2014.

She holds a Bachelor of Science from Texas A&M and a Lean Six Sigma – Yellow Belt certification.